Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1183P - Survival impact of concurrent chemoradiotherapy (CRT) with weekly cisplatin doses in patients with unresectable stage III non-small cell lung cancer (NSCLC) in a clinical referral center in Chile

Date

16 Sep 2021

Session

ePoster Display

Topics

Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Felipe Pinto

Citation

Annals of Oncology (2021) 32 (suppl_5): S939-S948. 10.1016/annonc/annonc728

Authors

F. Pinto1, C.J. Salinas Simonetti1, S. María Paz2, F. Orlandi3

Author affiliations

  • 1 Oncology Department, Hospital Clinico Universidad de Chile, 7560690 - Santiago/CL
  • 2 Oncology Department, Instituto Nacional del Tórax, 7560690 - Santiago/CL
  • 3 N/a, Orlandi Oncología, Santiago/CL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1183P

Background

In Chile, lung cancer is the second leading cause of cancer-related death. Most diagnoses are made in an advanced stage, with one third of all NSCLC cases in stage III unresectable disease, with a 5-year OS of 15%. The current standard of care for these patients has been platinum-based doublets with concurrent radiation therapy in combination with immunotherapy (IO).

Methods

We have performed a retrospective review over 517 clinical records of patients who were treated between 2014 – 2019 at “Instituto Nacional del Tórax”. Baseline clinical characteristics as well as therapy indicated and toxicity were recorded. Outcomes were analyzed by measuring progression free and overall survival. Toxicity was assessed by CTACAE v5.0 and response to treatment by RECIST 1.1 criteria.

Results

54% of the patients were men. 68% were in ECOG 0 performance status and 32% in ECOG 1, with a mean BMI of 26 kg/m2. All patients were smokers and 71% had some comorbidity in their medical history. 74% of NSCLC were adenocarcinomas and 26% squamous cell variant. 23% were stage IIIA, 54% IIIB, and 23% IIIC. Only 6 patients received adjuvant treatment before progressing to stage III disease. 86% received cisplatin (median 54.4 mg, range 40 to 60 mg) as a single dose combined with standard radiotherapy of 60 Gy averaged in 30 fractions in a concurrent modality in 91% of cases. 50% received durvalumab as maintenance. G3 toxicities were reported in 19.4%, corresponding to nausea and actinic pneumonitis. G2 toxicities were 37.1% for actinic pneumonitis and 11.4% for esophagitis. No grade 4 and 5 toxicities were reported. 82.8% progressed at 15 months on average and 17% maintained stable disease. The ORR was 77.1% among responders, the mOS was 23 months (95% CI [3.21-16.7]), and the mPFS was 10 months (95% CI [8.25- 11.75]).

Conclusions

Management of locally advance unresectable NSCLC has been changed since PACIFIC trial was published. Unfortunately, Public Health Insurance Systems does not cover access for IO. This local study was an attempt to demonstrate that classic concurrent CRT in medium-income countries could still have a relevant role in management.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S. María Paz: Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: Roche. F. Orlandi: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal and Institutional, Research Grant: Amgen; Financial Interests, Personal and Institutional, Research Grant: Astellas Pharma; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca; Financial Interests, Personal and Institutional, Research Grant: BMS; Financial Interests, Personal and Institutional, Research Grant: MSD; Financial Interests, Personal and Institutional, Research Grant: Pfizer; Financial Interests, Personal and Institutional, Research Grant: Roche; Financial Interests, Personal and Institutional, Research Grant: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.